Clinical trials: Botulinum toxin type A
Urinary Incontinence
Randomized Trial for Botox Urinary Incontinence
The purpose of this study is to determine how effective Botox is in reducing the amount of urine leaked and which dose of Botox is more effective and safe in those who have urinary urge incontinence.
- Trial name
- NCT00178191
- Testing
- Bladder diary, Questionnaires, Urodynamics
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Overactive Bladder, Urinary Urge Incontinence
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge
- Trial name
- NCT05308979
- Testing
- OnabotulinumtoxinA 100 UNT [Botox]
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Glabellar Lines, Lateral Canthal Lines
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
- Trial name
- READY-4 (NCT04225260)
- Testing
- botulinum toxin neuromodulator
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines, Wrinkles
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines. 1.
- Trial name
- NCT02718118
- Testing
- Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Wrinkles in Frontal Area
Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A
The objective of this study is to compare the field of effects of the botulinum toxins (Dysport® and Botox®) using two equivalence-ratios and to gather supportive information, such as more detailed data on the effectiveness in…
- Trial name
- NCT00989768
- Testing
- Botulinum Toxin Type A (Dysport®), Botulinum Toxin Type A/Botox®, Botulinum Toxin Type A/Dysport®
- Where
- Brazil
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Hexsel Dermatology Clinic
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Lateral Canthal Lines
Treatment of Moderate to Severe Lateral Canthal Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
- Trial name
- READY-2 (NCT04249687)
- Testing
- botulinum toxin
- Where
- 10 sites in United States, Canada
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Skin Aging
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
The purpose of this study is to determinate whether Xeomin® (Botulinum toxin Type A) is safe, effective and tolerable in woman aged 30 to 50 years old for treatment of mild, moderate or severe expression lines (wrinkles) in the…
- Trial name
- XEO-001/07 (NCT00986570)
- Testing
- Botulinum Toxin A
- Where
- Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Biolab Sanus Farmaceutica
Dermatological Non-Disease
Combination Facial Aesthetic Treatment in Millennials
With 63% of consumers willing to consider investing in facial aesthetics and 73% of consumers worldwide expecting to invest in aesthetic treatments in the upcoming year, it is imperative to explore patient satisfaction and…
- Trial name
- NCT04755595
- Testing
- Botox Cosmetic Injectable Product, Juvéderm Voluma XC, Juvéderm Volbella XC
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- State University of New York - Downstate Medical Center
Wrinkles
Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment of age-associated wrinkles and folds of…
- Trial name
- JUVE_BTX (NCT01269801)
- Testing
- onabotulinumtoxinA, JUVÉDERM
- Where
- 3 sites in United States, Canada
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- AboutSkin Dermatology and DermSurgery, PC
Glabellar Furrows
Botox Cosmetic and the Young Patient With Glabellar Furrows
The purpose of this study is to see if consistent treatment with Botox will lead to longer lasting effects. Botox is an injectable liquid that is approved by the U.S.
- Trial name
- NCT00856999
- Testing
- Botox
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Glabellar Frown Lines
Treatment of Moderate to Severe Glabellar Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
- Trial name
- READY-1 (NCT04249583)
- Testing
- botulinum toxin
- Where
- 14 sites in United States, Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Muscle Strength, Botulinum Toxins, Type A
Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies
The purpose of this feasibility study is to determine if temporary weakness of a small foot muscle caused by local injection of botulinum toxin into that muscle can be measured with a strain gauge in addition to the previously…
- Trial name
- NCT00822523
- Testing
- Botulinum Toxin, Type A, Saline
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Platysmal Bands
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands
Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.
- Trial name
- NCT04080882
- Testing
- AbobotulinumtoxinA dose 1, AbobotulinumtoxinA dose 2, AbobotulinumtoxinA dose 3
- Where
- 8 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Raynaud Phenomenon
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
- Trial name
- NCT03639766
- Testing
- AbobotulinumtoxinA, Saline solution
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Forehead Rhytides, Forehead Wrinkles
Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment
The purpose of this study is to determine whether there is a difference in clinical effect, duration of effect, level of discomfort and patient satisfaction in patients receiving topical anesthesia on one side of the forehead and…
- Trial name
- NCT03799484
- Testing
- Botulinum toxin type A, 2.5% lidocaine/2.5% prilocaine, petrolatum ointment
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Hypertensive Anal Canal
Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy
Idiopathic hypertensive anal canal is a fact and already exists presented by anal pain aggravated by defecation. It can be managed safely by closed lateral sphincterotomy but chemical sphincterotomy had a minor role in its…
- Trial name
- NCT00927849
- Testing
- lateral internal sphincterotomy (LIS), Glycerin trinitrate (GTN), botulinum toxin injection (BTX A)
- Where
- Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Spasmodic Dysphonia
Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia
One initial study has shown that Botulinum Toxin (BT) in combination with zinc supplementation may increase the duration of effects BT treatment. This initial study was in the context of facial aesthetics.
- Trial name
- NCT05892770
- Testing
- Zinc gluconate supplement, Botulinum toxin type A
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Florida